Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience (original) (raw)

2017, Hepatology (Baltimore, Md.)

Y90 transarterial radioembolization (TARE) is a transarterial locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival outcomes (OS) in a 1000-patient cohort acquired over a 15-year period. Between December 1, 2003 and March 31, 2017, 1000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child-Pugh (CP) class, United Network for Organ Sharing (UNOS) and Barcelona Clinic Liver Cancer (BCLC) staging systems. Albumin and bilirubin laboratory toxicities were compared to baseline. OS outcomes were reported using censoring and intention-to-treat methodologies. All treatments were outpatient, with a median 1 treatment per patient. 506 (51%) were CP A, 450 (45%) CP B, and 44 (4%) CP C. 263 (26%) patients were BCLC A, 152 (15%) B, 541 (54%) C, and 44 (4%) D. 368 (37%) were UNOS T1/T2, 169 (17%) T3, 147 (15...